FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:861-862 August 21, 2008 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kim, J. J. PubMed Citation

Despite great expectations and promising results of clinical trials, we still lack sufficient evidence of an effective vaccine against cervical cancer. Several strains of human papillomavirus (HPV) can cause cervical cancer, and two vaccines directed against the currently most important oncogenic strains (i.e., the HPV-16 and HPV-18 serotypes) have been developed. That is the good news. The bad news is that the overall effect of the vaccines on cervical cancer remains unknown. As Kim and Goldie¹ point out in this issue of the Journal, the real impact of HPV vaccination on cervical cancer will not be observable for decades.

Although . . . [Full Text of this Article]

Source Information

From the Journal of the Norwegian Medical Association, Oslo.

This article has been cited by other articles:

• Rothman, S. M., Rothman, D. J. (2009). Marketing HPV Vaccine: Implications for Adolescent Health and Medical Professionalism. JAMA 302: 781-786 [Abstract] [Full Text]  
• (2008). Vaccination against human papillomavirus. DTB 46: 89-93 [Abstract] [Full Text]  
• (2008). HPV Vaccination: Is It Cost-Effective?. JWatch Women's Health 2008: 1-1 [Full Text]